Tags

Type your tag names separated by a space and hit enter

The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
Stem Cells Transl Med. 2020 11; 9(11):1287-1302.SC

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused coronavirus disease 2019 (COVID-19) pandemic has become a global health crisis with an extremely rapid progress resulting in thousands of patients who may develop acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) treatment. So far, no specific antiviral therapeutic agent has been demonstrated to be effective for COVID-19; therefore, the clinical management is largely supportive and depends on the patients' immune response leading to a cytokine storm followed by lung edema, dysfunction of air exchange, and ARDS, which could lead to multiorgan failure and death. Given that human mesenchymal stem cells (MSCs) from various tissue sources have revealed successful clinical outcomes in many immunocompromised disorders by inhibiting the overactivation of the immune system and promoting endogenous repair by improving the microenvironment, there is a growing demand for MSC infusions in patients with COVID-19-related ARDS in the ICU. In this review, we have documented the rationale and possible outcomes of compassionate use of MSCs, particularly in patients with SARS-CoV-2 infections, toward proving or disproving the efficacy of this approach in the near future. Many centers have registered and approved, and some already started, single-case or phase I/II trials primarily aiming to rescue their critical patients when no other therapeutic approach responds. On the other hand, it is also very important to mention that there is a good deal of concern about clinics offering unproven stem cell treatments for COVID-19. The reviewers and oversight bodies will be looking for a balanced but critical appraisal of current trials.

Authors+Show Affiliations

Laboratory for Stem Cells and Reproductive Cell Biology, Department of Histology and Embryology, Ankara University Faculty of Medicine, Ankara, Turkey.Harvard Medical School, Boston, Massachusetts, USA. Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32779878

Citation

Can, Alp, and Hakan Coskun. "The Rationale of Using Mesenchymal Stem Cells in Patients With COVID-19-related Acute Respiratory Distress Syndrome: what to Expect." Stem Cells Translational Medicine, vol. 9, no. 11, 2020, pp. 1287-1302.
Can A, Coskun H. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Stem Cells Transl Med. 2020;9(11):1287-1302.
Can, A., & Coskun, H. (2020). The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Stem Cells Translational Medicine, 9(11), 1287-1302. https://doi.org/10.1002/sctm.20-0164
Can A, Coskun H. The Rationale of Using Mesenchymal Stem Cells in Patients With COVID-19-related Acute Respiratory Distress Syndrome: what to Expect. Stem Cells Transl Med. 2020;9(11):1287-1302. PubMed PMID: 32779878.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. AU - Can,Alp, AU - Coskun,Hakan, Y1 - 2020/07/21/ PY - 2020/04/17/received PY - 2020/06/06/revised PY - 2020/06/23/accepted PY - 2020/8/12/pubmed PY - 2020/12/22/medline PY - 2020/8/12/entrez KW - COVID-19 KW - acute respiratory distress syndrome KW - clinical trial KW - immunomodulation KW - inflammatory disease KW - mesenchymal stem cells SP - 1287 EP - 1302 JF - Stem cells translational medicine JO - Stem Cells Transl Med VL - 9 IS - 11 N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused coronavirus disease 2019 (COVID-19) pandemic has become a global health crisis with an extremely rapid progress resulting in thousands of patients who may develop acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) treatment. So far, no specific antiviral therapeutic agent has been demonstrated to be effective for COVID-19; therefore, the clinical management is largely supportive and depends on the patients' immune response leading to a cytokine storm followed by lung edema, dysfunction of air exchange, and ARDS, which could lead to multiorgan failure and death. Given that human mesenchymal stem cells (MSCs) from various tissue sources have revealed successful clinical outcomes in many immunocompromised disorders by inhibiting the overactivation of the immune system and promoting endogenous repair by improving the microenvironment, there is a growing demand for MSC infusions in patients with COVID-19-related ARDS in the ICU. In this review, we have documented the rationale and possible outcomes of compassionate use of MSCs, particularly in patients with SARS-CoV-2 infections, toward proving or disproving the efficacy of this approach in the near future. Many centers have registered and approved, and some already started, single-case or phase I/II trials primarily aiming to rescue their critical patients when no other therapeutic approach responds. On the other hand, it is also very important to mention that there is a good deal of concern about clinics offering unproven stem cell treatments for COVID-19. The reviewers and oversight bodies will be looking for a balanced but critical appraisal of current trials. SN - 2157-6580 UR - https://www.unboundmedicine.com/medline/citation/32779878/The_rationale_of_using_mesenchymal_stem_cells_in_patients_with_COVID_19_related_acute_respiratory_distress_syndrome:_What_to_expect_ L2 - https://doi.org/10.1002/sctm.20-0164 DB - PRIME DP - Unbound Medicine ER -